Highlights Alligator Bioscience AB

Equities

ATORX

SE0000767188

Delayed Nasdaq Stockholm Other stock markets 07:21:17 15/05/2024 pm IST			5-day change	1st Jan Change
0.877 ^SEK	+5.28%		+3.91%	+27.29%

14/05	Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer	CI
06/05	Transcript : Alligator Bioscience AB, Q1 2024 Earnings Call, May 06, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer	14/05	CI
Alligator Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05	CI
Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement	26/04	CI
Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs	26/03	CI
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4	07/03	CI
Alligator Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	08/02	CI
Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation	08/02	CI
Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer	29/01	CI
Alligator Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/23/26	CI
Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab	12/23/12	CI
Alligator Bioscience Obtains Orphan Status for Pancreatic Cancer Therapy in EU	21/23/21	MT
Alligator Bioscience Advances Research Partnership With Orion	31/23/31	MT
Alligator Bioscience AB Announces Technical Feasibility in the Second Program Under the Research Collaboration and License Agreement with Orion Corporation	31/23/31	CI
Alligator Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	13/23/13	CI
Alligator Bioscience AB Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist	30/23/30	CI
Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer	26/23/26	CI
Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023	05/23/05	CI
Alligator Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25	CI
Alligator Bioscience Announces Completion of Patient Enrolment in Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer and Confirms Timeline for Top-Line Data in First Quarter 2024	12/23/12	CI
Alligator Bioscience Announces FDA Authorization to Initiate Mitazalimab OPTIMIZE-2 Phase 2 Trial in Urothelial Carcinoma	03/23/03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alligator Bioscience AB

Equities

ATORX

SE0000767188

Highlights

Filters